Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gritstone bio, Inc. - Common Stock (NQ:GRTS)

0.0322 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gritstone bio, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
GRITSTONE INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Gritstone bio, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – GRTS
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Stockholder Alert: Robbins LLP Informs Investors of the Class Action Lawsuit Filed Against Gritstone Bio, Inc.
From Robbins LLP
Via GlobeNewswire
News headline image
Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
From Gritstone bio
Via GlobeNewswire
News headline image
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite
From Gritstone bio
Via GlobeNewswire
News headline image
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
From Gritstone bio
Via GlobeNewswire
News headline image
Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
From Gritstone bio
Via GlobeNewswire
News headline image
Genevant Sciences LNP Technology Used in samRNA Covid-19 Vaccine Candidate Behind Gritstone bio’s BARDA Award
From Genevant Sciences
Via GlobeNewswire
News headline image
Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio’s Next Generation COVID-19 Vaccine
From Gritstone bio
Via GlobeNewswire
News headline image
Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million
From Gritstone bio
Via GlobeNewswire
News headline image
Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
From Gritstone bio
Via GlobeNewswire
News headline image
Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates
From Gritstone bio
Via GlobeNewswire
News headline image
Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
From Gritstone bio
Via GlobeNewswire
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces New Board Member
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Predictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D. to the Board of Directors
From Predictive Oncology Inc.
Via GlobeNewswire
News headline image
Gritstone Reports Third Quarter 2022 Financial Results and Provides Business Update
From Gritstone bio
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.